Related by context. Frequent words. (Click for all words.) 89 dipropionate 73 2 methoxyestradiol 69 candidate brentuximab vedotin 68 candidates bavituximab 68 sodium Injection 68 FACTIVE R gemifloxacin 67 Panzem R 67 candidate Zenvia 67 refractory chronic lymphocytic 66 Locteron ® 66 R sorafenib tablets 66 Initiates Phase II 65 Inhalation Aerosol 65 inflammatory autoimmune diseases 65 Kuvan R 64 Receives Orphan Drug Designation 64 Antigen Express website 63 VEGFR2 inhibitor 63 Genasense ® oblimersen 63 phenylalanine ammonia lyase 63 Copegus R 63 KNS # 63 triple VEGF receptor 63 phenylketonuria PKU developed 63 PEG PAL PEGylated recombinant 62 TELINTRA 62 anticancer compound 62 AeroLEF R 62 candidate AP# 62 BioSante licensees 62 CONTAINS FORWARD LOOKING STATEMENTS 62 Coadministration 62 IS FOR INFORMATIONAL 62 BioGlue R 62 Release Tablets 62 Soliris TM eculizumab 62 Neo Urinary Conduit 62 histone deacetylase HDAC inhibitor 61 ALN TTR# 61 vosaroxin 61 Vytorin combines 61 Genasense R oblimersen 61 Rosetta dependence 61 Phase Ib clinical trials 61 Inc Therapeutic Competitors 61 Onalta 61 liposomal formulation 61 Currently RegeneRx 61 AS ESTIMATE ANTICIPATE BELIEVE 61 peripherally acting 61 PINNACLEDIGEST.COM S PAST PERFORMANCE 61 PLAN OR EXPECT 61 Meets Primary Endpoint 60 ZEGERID Capsules 60 Takeda Kyowa Hakko Kirin 60 MATERIALLY FROM ANY FUTURE 60 WHICH ARE NOT PURELY 60 chemotherapy induced neutropenia 60 www.pozen.com 60 YOUR LOCAL ANIMAL SHELTER 60 HepeX B 60 huC# DM4 60 Phase III Clinical Trial 60 PURPOSES ONLY AND DOES 60 Hematide TM 60 HCV protease inhibitor 60 Drug Candidate 60 non alcoholic steatohepatitis 60 OR SIMILAR STATEMENTS ARE 59 Ferumoxytol 59 visit www.PAREXEL.com 59 SHALL NOT CONSTITUTE AN 59 electrolytically generated source 59 AzaSite Plus 59 GVAX R 59 Panzem R NCD 59 JAK inhibitor 59 Lubiprostone 59 THE SITE WITHOUT 59 Generic Version 59 HGS ETR2 59 forodesine HCl 59 Visudyne R 59 IS NOT INDICATIVE OF 59 Moneylife.in website 59 BY THESE FORWARD 59 Gemzar ® 59 Biolex Therapeutics 59 Ticagrelor 59 6R BH4 59 Fast Track Status 59 Transcept Pharmaceuticals 59 HISTORICAL ARE FORWARD LOOKING 59 Entereg R 59 SECURITIES COMMISSION OR OTHER 59 gets USFDA nod 59 IS DEFINED IN 59 Therapeutic Competitors 59 pseudobulbar affect PBA 59 Voreloxin 59 Inhalation Solution